RecruitingNCT06823960
Study to Assess Effectiveness and Safety of Zanubrutinib for Patients With Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)
Studying MALT lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Principal Investigator
- Pier Luigi Zinzani, MDIRCCS Azienda Ospedaliero-Universitaria di Bologna
- Enrollment
- 59 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2025
Study locations (15)
- AOU SS Antonio e Biagio e Cesare Arrigo, Alessandria, Alessandria, Italy
- IRCCS-AOU di Bologna, Bologna, Bologna, Italy
- P.O. Garibaldi-Nesima_UOC Ematologia, Catania, Catania, Italy
- AO di Cosenza, P.O. "Annunziata" - UOC di Ematologia, Cosenza, Cosenza, Italy
- AOU di Ferrara_ UO di Ematologia - Dipartimento di Oncologia e Medicine Specialistiche, Ferrara, Ferrara, Italy
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS, Meldola, Forlì Cesena, Italy
- Istituto Clinico Humanitas IRCCS - UO Ematologia, Milan, Milano, Italy
- ASST Grande Ospedale Metropolitano Niguarda _ UOC Ematologia, Milan, MIlano, Italy
- IOV - Istituto Oncologico Veneto - IRCCS _UOC Oncologia1, Padova, Padova, Italy
- Ospedali Riuniti Villa Sofia - Cervello _ UO di Ematologia ad Indirizzo Oncologico, Palermo, Palermo, Italy
- Ospedale Santa Maria delle Croci- OU Ematologia di Ravenna, Ravenna, Ravenna, Italy
- Fondazione PTV Policlinico Tor Vergata- U.O.C. Patologie Linfoproliferative, Roma, Roma, Italy
- AOU Città della Salute e della Scienza, "Le Molinette" - Divisione di Ematologia, Torino, Torino, Italy
- Ospedale Ca' Foncello, Azienda ULSS n. 2 Marca trevigiana - UOC Ematologia Dipartimento di Medicina, Treviso, Treviso, Italy
- Azienda sanitaria universitaria Giuliano Isontina (ASU GI) - Ospedale Maggiore- SC (UCO) Ematologia, Trieste, Trieste, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06823960 on ClinicalTrials.govOther trials for MALT lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07554898Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT LymphomaZhejiang Cancer Hospital
- RECRUITINGPHASE2NCT06510309Rituximab Plus Venetoclax in Front Line Marginal Zone LymphomaGottfried von Keudell, MD PhD
- RECRUITINGPHASE2NCT07441993Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZLInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07372365Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.The First Affiliated Hospital of Soochow University
- RECRUITINGPHASE2NCT06796998Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)Izidore Lossos, MD
- RECRUITINGNCT06712459Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone LymphomaInternational Extranodal Lymphoma Study Group (IELSG)
- ACTIVE NOT RECRUITINGPHASE2NCT07480863Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZLCancer Institute and Hospital, Chinese Academy of Medical Sciences
- ACTIVE NOT RECRUITINGPHASE2NCT07247383Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT LymphomaSecond Affiliated Hospital, School of Medicine, Zhejiang University